Notable 52-Week Highs and Lows 11/22: (CHS) (ADI) (JACK) High; (PDCO) (NVO) Low

November 22, 2016 2:25 PM EST

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

52-Week High:
  • Chicos FAS (NYSE: CHS) $15.85. Chicos FAS reported Q3 EPS of $0.20, versus the analyst estimate of $0.13. Revenue for the quarter came in at $596.9 million versus the consensus estimate of $610.83 million. Comps fell 4.9 percent.

  • Analog Devices (Nasdaq: ADI) $74.85. Analog Devices reported Q4 EPS of $1.05, which was $0.16 better than the analyst estimate of $0.89. Revenue for the quarter came in at $1 million versus the consensus estimate of $942.58 million. Analog Devices sees Q1 2017 EPS of $0.68-$0.78, versus the consensus of $0.72. Analog Devices sees Q1 2017 revenue of $840-900 million, versus the consensus of $843.3 million.

  • Jack in the Box (Nasdaq: JACK) $106.96. Jack in the Box reported Q4 EPS of $1.03, versus the analyst estimate of $0.88. Revenue for the quarter came in at $398.42 million versus the consensus estimate of $398.71 million. Jack in the Box system same-store sales increased 2.0 percent for the quarter and exceeded the QSR sandwich segment by 1.3 percentage points for the comparable period. Jack in the Box sees GAAP FY2017 EPS of $4.55-$4.75, versus the consensus of $4.75.
52-Week Low:
  • Patterson Cos. (Nasdaq: PDCO) $36.46. Patterson reported Q2 EPS of $0.56, versus the analyst estimate of $0.60. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.44 billion. Patterson Cos. sees FY17 EPS of $2.25 - $2.35, versus the consensus of $2.64.

  • Novo Nordisk (NYSE: NVO) $31.50. Novo Nordisk lower after announcing that the US Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Xultophy 100/3.6. Xultophy 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Add Your Comment